|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||96.50 - 98.56|
|52 Week Range||64.72 - 126.98|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||534.29|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||111.33|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Neurocrine Biosciences, Inc. (NBIX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
CEO of Neurocrine Biosciences Inc (30-Year Financial, Insider Trades) Kevin Charles Gorman (insider trades) sold 80,000 shares of NBIX on 08/08/2019 at an average price of $95.31 a share. Continue reading...
- New Drug Application (NDA) is supported by data from pivotal Phase 3 studies of nearly 800 patients - Clinical trials in women with heavy menstrual bleeding (HMB) associated with uterine fibroids showed ...
Neurocrine (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Dow Jones futures: Beyond Meat stock dived late on mixed results and a share offering. RingCentral, Chegg rallied on earnings after closing in buy range. Apple earnings are on tap.
Neurocrine (NBIX) delivered earnings and revenue surprises of 54.17% and 14.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $180.5 Million with Approximately 31,600 TRx FDA Accepts Opicapone New Drug Application with PDUFA Date of April 26, 2020 Congenital Adrenal ...
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kevin Gorman became the CEO of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in 2008. This analysis aims first to...
The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.